<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id>
<journal-title-group>
<journal-title>Neurotherapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1933-7213</issn>
<issn pub-type="epub">1878-7479</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30414046</article-id>
<article-id pub-id-type="pmc">6277306</article-id>
<article-id pub-id-type="publisher-id">687</article-id>
<article-id pub-id-type="doi">10.1007/s13311-018-00687-z</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7145-7663</contrib-id>
<name>
<surname>Shieh</surname>
<given-names>Perry B.</given-names>
</name>
<address>
<phone>1-310-825-3264</phone>
<email>pshieh@mednet.ucla.edu</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution>Department of Neurology, </institution><institution>University of California, Los Angeles, </institution></institution-wrap>300 Medical Plaza, Suite B-200, Los Angeles, CA 90095 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>9</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2018</year>
</pub-date>
<volume>15</volume>
<issue>4</issue>
<fpage>840</fpage>
<lpage>848</lpage>
<permissions>
<copyright-statement>© The American Society for Experimental NeuroTherapeutics, Inc. 2018</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">Duchenne muscular dystrophy (DMD) is a progressive X-linked degenerative muscle disease due to mutations in the <italic>DMD</italic> gene. Genetic confirmation has become standard in recent years. Improvements in the standard of care for DMD have led to improved survival. Novel treatments for DMD have focused on reducing the dystrophic mechanism of the muscle disease, modulating utrophin protein expression, and restoring dystrophin protein expression. Among the strategies to reduce the dystrophic mechanisms are 1) inhibiting inflammation, 2) promoting muscle growth and regeneration, 3) reducing fibrosis, and 4) facilitating mitochondrial function. The agents under investigation include a novel steroid, myostatin inhibitors, idebenone, an anti-CTGF antibody, a histone deacetylase inhibitor, and cardiosphere-derived cells. For utrophin modulation, AAV-mediated gene therapy with GALGT2 is currently being investigated to upregulate utrophin expression. Finally, the strategies for dystrophin protein restoration include 1) nonsense readthrough, 2) synthetic antisense oligonucleotides for exon skipping, and 3) AAV-mediated micro/minidystrophin gene delivery. With newer agents, we are witnessing the use of more advanced biotechnological methods. Although these potential breakthroughs provide significant promise, they may also raise new questions regarding treatment effect and safety.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1007/s13311-018-00687-z) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Duchenne muscular dystrophy</kwd>
<kwd>Dystrophin</kwd>
<kwd>Gene therapy</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The American Society for Experimental NeuroTherapeutics, Inc. 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>